



King's Research Portal

DOI:

[10.1136/thoraxjnl-2015-207188](https://doi.org/10.1136/thoraxjnl-2015-207188)

Document Version

Publisher's PDF, also known as Version of record

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Suh, E-S., Mandal, S., Harding, R., Ramsay, M., Kamalanathan, M., Henderson, K., O'Kane, K., Douiri, A., Hopkinson, N. S., Polkey, M. I., Rafferty, G., Murphy, P. B., Moxham, J., & Hart, N. (2015). Neural respiratory drive predicts clinical deterioration and safe discharge in exacerbations of COPD. *Thorax*, 70(12), 1123-1130. <https://doi.org/10.1136/thoraxjnl-2015-207188>

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



OPEN ACCESS



► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/thoraxjnl-2015-207188>).

¹Lane Fox Respiratory Unit, Guy's and St Thomas' NHS Foundation Trust, London, UK

²Division of Asthma, Allergy and Lung Biology, King's College London, London, UK

³Emergency Department, Guy's and St Thomas' NHS Foundation Trust, London, UK

⁴Department of Acute Medicine, Guy's and St Thomas' NHS Foundation Trust, London, UK

⁵Division of Health and Social Care Research, King's College London, London, UK

⁶NIHR Respiratory Biomedical Research Unit at the Royal Brompton & Harefield NHS Foundation Trust and Imperial College, London, UK

Correspondence to

Dr Eui-Sik Suh, Lane Fox Respiratory Unit, St. Thomas' Hospital, Westminster Bridge Road, London SE1 7EH, UK; eui-sik.suh@nhs.net

Received 15 April 2015

Revised 22 June 2015

Accepted 27 June 2015

Published Online First 20 July 2015



► <http://dx.doi.org/10.1136/thoraxjnl-2015-207986>



CrossMark

To cite: Suh E-S, Mandal S, Harding R, et al. *Thorax* 2015;**70**:1123–1130.

ORIGINAL ARTICLE

Neural respiratory drive predicts clinical deterioration and safe discharge in exacerbations of COPD

Eui-Sik Suh,^{1,2} Swapna Mandal,^{1,2} Rachel Harding,¹ Michelle Ramsay,^{1,2} Meera Kamalanathan,¹ Katherine Henderson,³ Kevin O'Kane,⁴ Abdel Douiri,⁵ Nicholas S Hopkinson,⁶ Michael I Polkey,⁶ Gerrard Rafferty,² Patrick B Murphy,^{1,2} John Moxham,² Nicholas Hart^{1,2}

ABSTRACT

Rationale Hospitalised patients with acute exacerbation of COPD may deteriorate despite treatment, with early readmission being common.

Objectives To investigate whether neural respiratory drive, measured using second intercostal space parasternal muscle electromyography (EMG_{para}), would identify worsening dyspnoea and physician-defined inpatient clinical deterioration, and predict early readmission.

Methods Patients admitted to a single-site university hospital with exacerbation of COPD were enrolled. Spirometry, inspiratory capacity (IC), EMG_{para}, routine physiological parameters, modified early warning score (MEWS), modified Borg scale for dyspnoea and physician-defined episodes of deterioration were recorded daily until discharge. Readmissions at 14 and 28 days post discharge were recorded.

Measurements and main results 120 patients were recruited (age 70±9 years, forced expiratory volume in 1 s (FEV₁) of 30.5±11.2%). Worsening dyspnoea, defined as at least one-point increase in Borg scale, was associated with increases in EMG_{para%max} and MEWS, whereas an increase in EMG_{para%max} alone was associated with physician-defined inpatient clinical deterioration. Admission-to-discharge change (Δ) in the normalised value of EMG_{para} (ΔEMG_{para%max}) was inversely correlated with ΔFEV₁ (r=−0.38, p<0.001) and ΔIC (r=−0.44, p<0.001). ΔEMG_{para%max} predicted 14-day readmission (OR 1.13, 95% 1.03 to 1.23) in the whole cohort and 28-day readmission in patients under 85 years (OR 1.09, 95% CI 1.01 to 1.18). Age (OR 1.08, 95% CI 1.03 to 1.14) and 12-month admission frequency (OR 1.29, 1.01 to 1.66), also predicted 28-day readmission in the whole cohort. **Conclusions** Measurement of neural respiratory drive by EMG_{para} represents a novel physiological biomarker that may be helpful in detecting inpatient clinical deterioration and identifying the risk of early readmission among patients with exacerbations of COPD.

Trial registration NCT01361451.

INTRODUCTION

Acute exacerbations of COPD (AECOPD) are common, accounting for 12.5% of emergency admissions in the UK¹ with an in-hospital mortality of up to 10%.² Eighteen percent of patients with AECOPD present to the emergency department with acute hypercapnic respiratory failure³ and a further 5% will develop late respiratory acidosis.

Key messages

What is the key question?

- Can non-invasive measurement of neural respiratory drive identify clinical deterioration and the risk of early readmission in patients admitted with exacerbation of COPD?

What is the bottom line?

- Neural respiratory drive, measured by second intercostal space parasternal muscle electromyography, is a physiological biomarker of worsening breathlessness and physician-defined clinical deterioration in COPD exacerbations, and may predict early readmission.

Why read on?

- The results of a large physiological observational cohort study are presented, validating a novel physiological biomarker that represents the balance between the load and the capacity of the respiratory muscle pump during exacerbations of COPD.

Twenty percent of hospitalised patients with AECOPD are readmitted within 28 days,^{4 5} and financial penalties are now in operation for acute care hospitals in the UK and USA for readmissions within 30 days.^{6 7} It is a health economic priority to identify COPD treatment failure promptly and reduce readmissions, and biomarkers that can achieve this will therefore be of significant clinical value.

Previous studies have reported the patient characteristics that predict readmission among hospitalised patients with COPD,^{2 8–11} but these are limited by their dependence on non-modifiable parameters, rather than on the trajectory of response to treatment. In addition, early-warning scores,¹² often used to track inpatient clinical deterioration and trigger escalation of care, vary in their ability to predict outcomes such as critical care admission and hospital mortality,¹³ limiting the usefulness of these approaches.

More advanced physiological measurements of elastic and threshold respiratory load are difficult

Chronic obstructive pulmonary disease

during an acute exacerbation as invasive monitoring of pleural pressure is poorly tolerated. In addition, the measurement of ventilation in flow-limited patients characterised by neuroventilatory uncoupling, as a result of severe hyperinflation, has significant caveats and therefore the non-invasive measurement of neural respiratory drive (NRD), which is a direct reflection of the imbalance between respiratory muscle load and capacity, would be a preferred option. Indeed, NRD as an advanced physiological biomarker, provides a direct measure of the balance between respiratory muscle load and capacity,¹⁴ and has gained increasing attention in the acute setting.¹⁵

Recently, surface electromyography (EMG) of the second intercostal space parasternal muscles (EMG_{para}) has been used as a non-invasive alternative to the invasive oesophageal measurement¹⁶ of NRD in patients with COPD, asthma and cystic fibrosis.^{15 17 18} Murphy *et al*¹⁵ previously showed, in a pilot feasibility study of this technique, that the change in NRD during hospital admission was a biomarker of physician-defined clinical deterioration, and furthermore, change in NRD from admission to discharge identified patients with COPD who were readmitted within 14 days. However, this previous study was in a small group of selected patients with COPD, with the majority of patients having only a single pair of NRD measurements made during their hospital admission.

We therefore hypothesised that, in a large, prospective observational cohort study of patients hospitalised with exacerbation of COPD, changes in daily measurements of NRD between hospital admission and discharge would predict readmission within 14 and 28 days. We further hypothesised that change in NRD would objectively identify worsening dyspnoea and physician-defined clinical deterioration.

METHODS

Patients

The study was approved by the London-Bentham Research Ethics Committee and participants provided written informed consent. The authors registered the study as an observational cohort study (NCT01361451). Patients with a physician diagnosis of acute exacerbation of COPD, defined according to clinical features and basic investigations,¹ were enrolled within 12 h of admission to a UK teaching hospital. The requirement for admission was determined by the attending physician. Patients were excluded if they had another cause for their acute

admission (eg, acute heart failure, PE), cognitive impairment, active cancer or significant psychosocial factors.

Admission data

Demographic and anthropometric data were collected. FEV₁, FVC and inspiratory capacity (IC)¹⁹ were measured using a pneumotachometer (3830, Hans-Rudolph, Shawnee, USA) or a handheld spirometer (Micro, Carefusion, Basingstoke, UK) according to international standards.²⁰ Symptoms were assessed using the Medical Research Council (MRC) Dyspnoea scale,²¹ the modified Borg scale for dyspnoea²² and the COPD Assessment Test (CAT).²³ Standard physiological observations (respiratory rate, heart rate, oxygen saturation, body temperature and blood pressure) were collected; an aggregate score derived from these was recorded as the modified early warning score (MEWS), according to local protocol.


EMG_{para} measurement

EMG_{para} was measured with patients in a semi-recumbent or seated position, as previously described.¹⁵ After skin preparation, two surface electrodes (Blue Sensor Q, Ambu, St Ives, UK) were placed in the second intercostal spaces, immediately lateral to the sternum. The skin was marked to allow placement of electrodes in an identical position throughout the study. Nasal cannulae connected to a differential pressure transducer (Technical services, Lane Fox Respiratory Unit, London, UK) identified inspiration and expiration phases (figure 1). EMG_{para} signals were amplified and sampled at 2 kHz (Dual Bioamp and Powerlab, AD Instruments, Chalgrove, UK). Signals were analysed using Labchart software (AD Instruments) on a personal computer. The peak root mean square EMG_{para} activity for each inspiration was averaged over 1 min of tidal breathing and normalised to a value of EMG_{para} obtained during a maximal inspiratory sniff manoeuvre, obtained before each measurement.¹⁵ Two measures of NRD were derived, including (1) EMG_{para%max}, the mean peak inspiratory tidal EMG_{para} normalised to the maximal manoeuvre; and (2) NRDI (Neural Respiratory Drive Index), the product of EMG_{para%max} and respiratory rate.¹⁵

Study protocol

EMG_{para}, modified Borg scale, FEV₁, FVC and IC were measured at least daily, between admission and medical fitness for

Figure 1 Representative trace of nasal pressure and second intercostal space parasternal electromyogram during tidal breathing in a patient with COPD during an exacerbation. P_{np}, nasal pressure; EMG_{para}, parasternal electromyogram; RMS_{para}, root mean square of EMG_{para}.



discharge, and at least 2 h after the last bronchodilator dose. Medical fitness for discharge was determined by the senior attending physician, which was either senior resident or consultant. Supplemental oxygen was provided as instructed by the attending physicians. Patients were settled at rest for 7 min before EMG_{para} traces were acquired for analysis. Patients requiring non-invasive ventilation (NIV) had measurements taken after 10 min off NIV. The attending physicians, who were blinded to EMG_{para} data, were asked to provide an opinion regarding clinical improvement or deterioration between successive assessments. EMG_{para} data were analysed after patients' discharge from hospital. Data for readmissions and deaths were obtained from patients and their relatives, and from medical records. Admission-to-discharge changes in EMG_{para%max} and NRDI were expressed as Δ EMG_{para%max} and Δ NRDI, respectively. Changes in EMG_{para%max} and NRDI between consecutive inpatient measurements were denoted Δ EMG_{para%max,cons} and Δ NRDI_{cons}, respectively.

Primary endpoint and power calculation

Although this was an observational cohort study, an a priori primary endpoint of 28-day readmission was taken as this was considered to have major clinical relevance to the current financial penalty systems for readmission in the UK and USA. Secondary endpoints were 14-day readmission and clinical deterioration, defined by (1) at least one-point increase in Borg scale²⁴ between consecutive recordings, or (2) attending physician opinion. A sample size of 120 was determined from published pilot data¹⁵ with a presumed 28-day readmission rate of 20% to detect a difference in NRDI of 203/min between readmitted and non-readmitted patients with a power of 80%.

Statistical analysis

Paired data were analysed using t or Wilcoxon signed-rank tests. Readmitted and non-readmitted groups were compared using independent t or Mann–Witney U tests. Death after discharge without early readmission was analysed together with readmissions. Logistic regression and receiver-operator characteristic (ROC) analyses were used to identify, and test the utility of, predictors of readmission. Kaplan–Meier plots and log rank tests were used to analyse time to readmission. Generalised linear mixed model (GLMM) analyses were used to assess the association between Δ EMG_{para%max,cons} and episodes of worsening dyspnoea or with physician-defined deterioration. For the purposes of this study, death was analysed with the readmission data.

RESULTS

Admission, clinical course and readmission data

A total of 131 patients were enrolled between January 2011 and September 2013 (see online supplementary figure E1), and 120 patients completed the study between admission and discharge (table 1). Twenty (16.7%) patients were unable to perform FEV₁ and FVC manoeuvres at admission, while 27 (22.5%) patients could not perform admission IC manoeuvres. Three (2.5%) patients declined arterial blood gas sampling. Eight (6.7%) patients required NIV or high-dependency care following admission to hospital. There were no patients who received high-flow humidified oxygen therapy. A further three (2.5%) patients deteriorated more than 12 h after admission and required NIV. Median length of hospital stay was 3 (IQR 2–6) days. Median interval from the date of medical fitness for discharge to the date of discharge was 0 (IQR 0–1) days. One patient died 3 days after discharge from hospital.

Table 1 Baseline characteristics at admission to hospital

Anthropometrics, smoking and previous exacerbations	
Age (years)	70 (9)
Male (%)	58 (48.3)
BMI (kg/m ²)	25.3 (7.2)
Current smokers (%)	47 (39.2)
Smoking history (pack years)	40 (25–50)
Exacerbation frequency (/12 months)	3 (1–5)
Hospital admission frequency (/12 months)	1 (0–2)
Current exacerbation history	
Duration of symptoms (days)	4 (2–7)
Systemic steroids prior to admission (%)	26 (21.7)
Antibiotics prior to admission (%)	30 (25.0)
Comorbidities	
Ischaemic heart disease (%)	34 (28.3)
Cerebrovascular disease (%)	13 (10.8)
Hypertension (%)	53 (44.2)
Diabetes mellitus (%)	20 (16.7)
Disease severity	
GOLD stage 2 (%)*	4 (4)
GOLD stage 3 (%)*	36 (36)
GOLD stage 4 (%)*	60 (60)
MRC dyspnoea grade	4 (4–5)
Admission investigations	
Arterial blood gases†	
pH	7.39 (0.06)
p _a CO ₂ (kPa)	5.82 (1.39)
p _a O ₂ (kPa)	8.83 (2.98)
Bicarbonate (mEq/L)	25.7 (3.8)
Base excess (mmol/L)	0.63 (3.1)
Lactate (mmol/L)	1.7 (1.5)
Routine laboratory tests	
C-reactive protein (mmol/L)	65 (100)
Creatinine (μmol/L)	72 (45)
Fibrinogen (mmol/L)‡	4.6 (1.5)
Leucocytes (×10 ³ /μL)	11.9 (4.8)
Neutrophils (×10 ³ /μL)	8.4 (5.0)
Eosinophils (×10 ³ /μL)	0.3 (0.7)
Haemoglobin (g/dL)	13.8 (1.7)
Platelets (×10 ⁹ /L)	259 (87)
Radiographic consolidation	25 (20.8)
Length of hospital stay (days)	3 (2–6)
Deaths within 28 days (%)	1 (0.8)
Readmission within 28 days (%)	26 (21.7)
Deaths within 14 days (%)	1 (0.8)
Readmission within 14 days (%)	15 (12.5)

Mean (SD), Median (IQR) or N (%).

*N=100.

†N=117.

‡N=68.

BMI, body mass index; GOLD, Global initiative for chronic Obstructive Lung Disease; MRC, Medical Research Council; p_aCO₂, arterial partial pressure of carbon dioxide; p_aO₂, arterial partial pressure of oxygen.

Fourteen-day and 28-day readmission rates were 12.5% and 21.7%, respectively. The single death was analysed with the readmission data.

Early warning scores, symptom scores and physiological data

MEWS, modified Borg scale and CAT scores all improved from admission to discharge (table 2). FEV₁, FVC and IC increased over this period, with a concomitant fall in EMG_{para%max} and NRDI (table 2).

Chronic obstructive pulmonary disease

Table 2 Physiological measurements at admission and discharge

	Admission	Discharge	p Value
Spirometry			
FEV ₁ (L)*	0.69 (0.28)	0.75 (0.31)	<0.001
FVC (L)*	1.51 (0.56)	1.63 (0.54)	0.02
FEV ₁ %predicted (%)*	30.5 (11.2)	33.7 (12.2)	<0.001
FEV ₁ /FVC ratio (%)*	47.4 (12.8)	48.9 (13.2)	0.184
Inspiratory capacity (L)†	1.39 (0.58)	1.56 (0.63)	<0.001
Symptom scores			
Modified Borg scale	3 (2–5)	2 (1–3)	<0.001
COPD assessment test	29 (24–32.75)	24 (17–29)	<0.001
Routine observations			
S _p O ₂ (%)	92.6 (3.5)	93.4 (2.8)	0.024
Temperature (°C)	36.5 (0.6)	36.3 (0.5)	0.023
Heart rate (/min)	97.2 (15.8)	84.8 (12.9)	<0.001
Respiratory rate (/min)	23.1 (4.3)	20.4 (2.4)	0.024
MEWS	3 (2–5)	2 (1–3)	<0.001
Parasternal EMG parameters			
Sniff (maximum) EMG (μV)	74.8 (37.3)	76.5 (39.1)	0.35
EMG _{para%max} (%)	17.4 (8.2)	15.8 (7.3)	0.017
NRDI (/min)	372 (205)	329 (196)	0.018

Values are expressed as mean (SD) or median (IQR).

*N=100.

†N=93.

EMG, electromyography; MEWS, medical early warning score; NRDI, Neural Respiratory Drive Index; S_pO₂, transcutaneous oxygen saturation.**Relationship between NRD, physiological parameters and dyspnoea**

Admission-to-discharge change (Δ) in EMG_{para%max} was inversely correlated with Δ FEV₁ ($r=-0.38$, $p<0.001$), Δ FVC ($r=-0.31$, $p=0.003$) and Δ IC ($r=-0.44$, $p<0.001$) (figure 2). However, there was no correlation between Δ EMG_{para%max} and Δ modified Borg scale, Δ CAT score or Δ MEWS. Increases in FEV₁ and IC were independently associated with reductions in EMG_{para%max} on multiple linear regression analysis (Δ FEV₁ standardised coefficient $\beta=-0.36$, $p=0.001$; Δ IC $\beta=-0.26$, $p=0.019$). Δ EMG_{para%max} was weakly correlated with age ($r=+0.24$, $p=0.009$). Δ NRDI was weakly inversely correlated with Δ FEV₁ ($r=-0.30$, $p=0.004$), Δ FVC ($r=-0.29$, $p=0.007$) and Δ IC ($r=-0.40$, $p<0.001$), as well as with body mass index ($r=-0.27$, $p=0.005$). There were no correlations between Δ NRDI and Δ Borg scale or Δ MEWS.

Predictors of readmission within 28 days

Twenty-seven (22.5%) patients were readmitted or died within 28 days of hospital discharge. Independent sample analysis showed significant differences in age, MRC grade, admission haemoglobin levels, hospital admission frequency in the previous 12 months (admission frequency), Δ EMG_{para%max} and Δ NRDI between readmitted and non-readmitted groups at 28 days (table 3). There were no significant differences in the values of EMG_{para%max} and NRDI at discharge between the two groups. With the exception of the MRC grade, univariate analysis demonstrated that all of these parameters predicted readmission at 28 days (table 4). However, in multivariable stepwise logistic regression analysis, only age and admission frequency predicted 28-day readmission (adjusted OR 1.08, 95% CI 1.03 to 1.14, $p=0.004$, and adjusted OR 1.29, 95% CI 1.01 to 1.66; $p=0.043$, respectively). Change in EMG_{para%max} between admission and discharge did not predict 28-day readmission in the whole cohort. The rate of radiographic




Figure 2 Relationship between admission-to-discharge change in EMG_{para%max} and changes in (A) FEV₁, (B) FVC and (C) IC. EMG_{para%max}, 1 min mean magnitude of rectified inspiratory parasternal EMG activity normalised to a maximal manoeuvre; IC, inspiratory capacity.

consolidation was not significantly different between the two groups (11.1% for the readmitted vs 23.7% for the non-readmitted group; $p=0.16$).

In accordance with the correlation, albeit weak, between Δ EMG_{para%max} and age, a post hoc, exploratory analysis was performed among patients below an arbitrary age cut-off of 85 years ($n=112$). There were 23 (20.5%) readmissions within 28 days among these patients. Under these circumstances, older age (adjusted OR 1.10, 95% CI 1.02 to 1.16; $p=0.017$) and increasing EMG_{para%max} between admission and discharge (adjusted OR 1.09, 95% CI 1.01 to 1.18, $p=0.023$) were predictive of 28-day readmission. ROC analysis for the prediction of 28-day readmission in patients under 85 years produced an area under the ROC curve (AUC) of 0.70 for age and 0.66 for Δ EMG_{para%max}.

Predictors of readmission within 14 days

Sixteen (13.3%) patients were readmitted or died within 14 days of discharge. There were differences in MRC grade and

Table 3 Differences between readmitted and non-readmitted patients within 28 days

	28-day readmission N=27	Non-readmitted at 28 days N=93	p Value
Age (years)	75 (9)	68 (9)	0.001
MRC dyspnoea grade	5 (4–5)	4 (3–5)	0.013
Admission frequency (/12 months)	1 (1–3)	0 (0–2)	0.006
Admission haemoglobin (g/dL)	13.1 (1.8)	14.0 (1.7)	0.017
$\Delta\text{EMG}_{\text{para}\% \text{max}}$ (%)	+1.5 (8.4)	–2.4 (7.2)	0.018
ΔNRDI (/min)	+28 (217)	–64 (189)	0.032
$\Delta\text{Modified Borg scale}$	–2 (–2.5 to –2)	–1 (–3 to –1)	0.58
ΔCAT	–7 (–12 to 0)	–5 (–9 to 0)	0.30
$\Delta\text{Respiratory rate}$ (/min)	–3.2 (5.3)	–2.6 (4.0)	0.50

Values are expressed as mean (SD) or median (IQR).

CAT, COPD Assessment Test; $\text{EMG}_{\text{para}\% \text{max}}$, 1 min mean magnitude of rectified inspiratory parasternal EMG activity normalised to a maximal manoeuvre; MRC, Medical Research Council; NRDI, Neural Respiratory Drive Index.

$\Delta\text{EMG}_{\text{para}\% \text{max}}$ between the readmitted and non-readmitted groups (table 5), but MRC grade did not predict 14-day readmission in the univariate logistic regression model (table 6). Only admission-to-discharge increases in $\text{EMG}_{\text{para}\% \text{max}}$ (adjusted OR 1.12, 95% CI 1.03 to 1.21, $p=0.005$) predicted 14-day readmission on multivariable stepwise logistic regression analysis. ROC analysis for the prediction of 14-day readmission gave an AUC of 0.70 for $\Delta\text{EMG}_{\text{para}\% \text{max}}$. By contrast, AUC for ΔFEV_1 and ΔIC were 0.57 and 0.56, respectively (figure 3). The failure of $\Delta\text{EMG}_{\text{para}\% \text{max}}$ to fall by more than 3.1% between admission and discharge had a sensitivity of 93.8% and a specificity of 41.3% to detect 14-day readmission, with a positive predictive value (PPV) of 19.7% and a negative predictive value (NPV) of 97.7%. Again, there was a non-significant difference in the rate of radiographic consolidation between the groups (6.25% for the readmitted vs 23.1% for the non-readmitted group, $p=0.123$). Kaplan–Meier analysis showed that patients whose $\text{EMG}_{\text{para}\% \text{max}}$ failed to fall by less than 3.1% between admission and discharge had a shorter time to readmission than those whose $\text{EMG}_{\text{para}\% \text{max}}$ fell by more than 3.1% (log rank test $p=0.03$) (figure 4).

When ΔNRDI was used instead of $\Delta\text{EMG}_{\text{para}\% \text{max}}$ in the regression model as a measure of NRD, it also predicted 14-day readmission or death (ΔNRDI : OR 1.003, 95% CI 1.001 to

Table 5 Differences between readmitted and non-survivors and non-readmitted survivors within 14 days

	14-day readmission or death N=16	Non-readmitted at 14 days N=104	p Value
MRC dyspnoea grade	5 (4–5)	4 (4–5)	0.039
$\Delta\text{EMG}_{\text{para}\% \text{max}}$ (%)	+3.6 (8.3)	–2.3 (7.2)	0.003
ΔNRDI (/min)	+71 (221)	–61 (190)	0.012
$\Delta\text{Modified Borg scale}$	–0.25 (–2 to 1)	–1 (–3 to 0)	0.12
ΔCAT	–8.5 (–11 to –2)	–5 (–9 to 1)	0.16
$\Delta\text{Respiratory rate}$ (/min)	–2.6 (3.5)	–2.8 (4.4)	0.87

Values are expressed as mean (SD) or median (IQR).

CAT, COPD Assessment Test; $\text{EMG}_{\text{para}\% \text{max}}$, 1 min mean magnitude of rectified inspiratory parasternal EMG activity normalised to a maximal manoeuvre; MRC, Medical Research Council; NRDI, Neural Respiratory Drive Index.

1.006, $p=0.01$). ROC analysis for the prediction of 14-day readmission gave an AUC of 0.70 for NRDI.

Detection of in-hospital clinical deterioration

A total of 475 pairs of consecutive EMG_{para} data were acquired from the 122 patients who provided at least one pair of analysable data; although 120 patients completed investigations between hospital admission and discharge, two further patients gave at least one pair of analysable data before withdrawal from the study. Patients had a median of three pairs of measurements (range 1–23) between admission and discharge. There were 116 episodes of worsening dyspnoea, defined as at least one-point increase in Borg scale. On univariate GLMM analysis, an increase in MEWS ($\Delta\text{MEWS}_{\text{cons}}$) and in $\text{EMG}_{\text{para}\% \text{max}}$ ($\Delta\text{EMG}_{\text{para}\% \text{max}, \text{cons}}$) between consecutive recordings was associated with symptomatic deterioration (table 7). Multivariable GLMM analysis showed that $\Delta\text{MEWS}_{\text{cons}}$ (adjusted OR 1.36, 95% CI 1.01 to 1.84, $p=0.04$) and $\Delta\text{EMG}_{\text{para}\% \text{max}, \text{cons}}$ (adjusted OR 1.07, 95% CI 1.01 to 1.14, $p=0.027$) were independently associated with worsening of dyspnoea. Multivariable GLMM analysis showed that $\Delta\text{EMG}_{\text{para}\% \text{max}, \text{cons}}$ (coefficient 0.05, 95% CI 0.01 to 0.09, $p=0.024$) and $\Delta\text{IC}_{\text{cons}}$ (coefficient –1.11, 95% CI –2.19 to –0.03, $p=0.044$) were independently associated with changes in Borg scale of any magnitude between consecutive recordings.

There were 35 episodes of physician-defined deterioration. Only an increase in $\text{EMG}_{\text{para}\% \text{max}}$ between consecutive measurements was associated with physician-defined deterioration ($\Delta\text{EMG}_{\text{para}\% \text{max}, \text{cons}}$ OR 1.030, 95% CI 1.003 to 1.055, $p=0.03$).

Table 4 Univariate logistic regression analysis for predictors of 28-day readmission

	OR	p Value	95% CI
Age	1.09	0.002	1.03 to 1.15
Hospital admission frequency	1.35	0.013	1.07 to 1.71
Haemoglobin	0.73	0.020	0.56 to 0.95
$\Delta\text{EMG}_{\text{para}\% \text{max}}$	1.08	0.022	1.01 to 1.15
ΔNRDI	1.002	0.036	1.000 to 1.005
$\Delta\text{Modified Borg scale}$	1.07	0.49	0.88 to 1.29
ΔCAT	0.98	0.82	0.93 to 1.03
$\Delta\text{Respiratory rate}$	0.97	0.50	0.88 to 1.07

CAT, COPD Assessment Test; $\text{EMG}_{\text{para}\% \text{max}}$, 1 min mean magnitude of rectified inspiratory parasternal EMG activity normalised to a maximal manoeuvre; NRDI, neural respiratory drive index.

Table 6 Univariate logistic regression analysis for predictors of 14-day readmission

	OR	p Value	95% CI
MRC dyspnoea grade	1.86	0.09	0.92 to 3.76
$\Delta\text{EMG}_{\text{para}\% \text{max}}$	1.12	0.005	1.03 to 1.21
ΔNRDI	1.003	0.014	1.001 to 1.006
$\Delta\text{Modified Borg scale}$	1.23	0.10	0.96 to 1.57
ΔCAT	0.99	0.67	0.92 to 1.05
$\Delta\text{Respiratory rate}$ (/min)	1.01	0.87	0.89 to 1.15

Values are expressed as mean (SD) or median (IQR).

CAT, COPD Assessment Test; $\text{EMG}_{\text{para}\% \text{max}}$, 1 min mean magnitude of rectified inspiratory parasternal EMG activity normalised to a maximal manoeuvre; MRC, Medical Research Council; NRDI, Neural Respiratory Drive Index.

Chronic obstructive pulmonary disease




Figure 3 Receiver-operator curves for prediction of 14-day readmission for (A) $\Delta\text{EMG}_{\text{para}\% \text{max}}$, (B) ΔFEV_1 , and (C) ΔIC . $\text{EMG}_{\text{para}\% \text{max}}$, 1 min mean magnitude of rectified inspiratory parasternal EMG activity normalised to a maximal manoeuvre; IC, inspiratory capacity; ROC, receiver-operator curve; AUC, area under the receiver-operator curve.

DISCUSSION

In this single-centre validation study of an advanced physiological biomarker performed in an unselected cohort of acutely unwell patients with COPD, the failure of NRD to fall between admission and discharge predicted readmission within 14 days of discharge. Furthermore, this failure was predictive of readmission within 28 days in those patients under 85 years of age, but not in the cohort as a whole. In addition to the utility of this test to predict clinical outcome following hospital discharge, an increase in NRD between consecutive daily measurements detected episodes of worsening dyspnoea and physician-defined in-hospital clinical deterioration. The physiological rationale of employing NRD was strongly supported by the relationship with change in respiratory muscle physiological load between admission and discharge.




Figure 4 Time-to-readmission Kaplan-Meier plots for patients whose $\text{EMG}_{\text{para}\% \text{max}}$ fell by more than 3.1% between admission and discharge (solid line), and those whose $\text{EMG}_{\text{para}\% \text{max}}$ fell by less than 3.1% (dotted line). $\text{EMG}_{\text{para}\% \text{max}}$, 1 min mean magnitude of rectified inspiratory parasternal EMG activity normalised to a maximal manoeuvre.

Critique of the method

Every attempt was made to enrol consecutive eligible patients with a screening to recruitment ratio of 3.4:1 achieved, which is acceptable for such an observational detailed physiological study. Few of the patients enrolled into this study required non-invasive or invasive ventilation at admission, which adds to the generalisability of this study and indeed the current cohort was wholly representative of UK patients admitted to the acute medical wards.² Patients presenting in acute hypercapnic respiratory failure were frequently unable to provide written informed consent, and the study did not have ethical approval for proxy assent and retrospective patient consent.

In line with our previous work,¹⁵ up to one-fifth of patients were unable to perform forced respiratory manoeuvres at admission, which supports the clinical rationale for non-invasive measurements, such as EMG_{para} , being performed during resting tidal breathing. This could be accommodated into the routine monitoring of acutely unwell patients with COPD as a measure of the respiratory load-capacity balance. The acquisition of respiratory EMG needs to be performed in a standardised manner as variations in electrode position and skin preparation can have a small influence on the magnitude of the signals; however, we have previously published data demonstrating the reproducibility of EMG_{para} .^{15 18} Although there was variability in the value of the maximal EMG obtained during the sniff procedure between admission and discharge (see online supplementary figure E2), there was no overall increase during the course of the hospital stay and therefore it is unlikely that the reduction in $\text{EMG}_{\text{para}\% \text{max}}$ between admission and discharge was driven by a fall in the maximal EMG_{para} .

Table 7 Generalised linear mixed modelling analysis for factors associated with clinical deterioration in symptoms as defined by ≥ 1 point increase in Borg scale

	Adjusted OR	p Value	95% CI
$\Delta\text{MEWS}_{\text{cons}}$	1.157	0.048	1.001 to 1.338
$\Delta\text{EMG}_{\text{para}\% \text{max, cons}}$ (%)	1.05	0.001	1.02 to 1.08

$\Delta\text{EMG}_{\text{para}\% \text{max, cons}}$, change in $\text{EMG}_{\text{para}\% \text{max}}$ between consecutive inpatient measurements; $\text{EMG}_{\text{para}\% \text{max}}$, 1-min mean magnitude of rectified inspiratory parasternal EMG activity normalised to a maximal manoeuvre; $\Delta\text{MEWS}_{\text{cons}}$, change in modified early warning score between consecutive measurements.

Clinical applicability of the findings

Readmission within 14 days

Although the cut-off level for $\Delta\text{EMG}_{\text{para}\% \text{max}}$ of -3.1% has a low PPV for 14-day readmission, the high NPV indicates that NRD has clinical utility as a risk-stratification tool for patients with COPD being discharged from hospital. Patients whose $\text{EMG}_{\text{para}\% \text{max}}$ falls by more than 3.1% during hospital admission are at very low risk of 14-day readmission and indeed these patients have greater time to readmission. The selected cut-off value is similar in magnitude to the fall in $\text{EMG}_{\text{para}\% \text{max}}$ observed amongst non-readmitted patients in the pilot study of Murphy *et al*,¹⁵ indicating the reproducibility of this technique. Pharmacological and technological therapies could be used in future studies to target a reduction in EMG_{para} , with the aim of optimising pulmonary mechanics, which could potentially reduce readmission rates. The cut-off value of -3.1% requires further prospective validation to become a useful clinical tool.

Readmission within 28 days

The admission-to-discharge change in NRD failed to predict 28-day readmission across all age groups. This is perhaps unsurprising as several previous studies have shown that age^{25 26} and admission frequency^{8 27} are strongly predictive of readmission. In elderly patients, functional impairment and the burden of chronic disease²⁸ play a major role in influencing readmission and, in the current study, it appears to be more influential than the failure to enhance the respiratory muscle load–capacity balance. The current data support the concept that the inpatient trajectory of NRD was a key factor influencing 14-day readmission in all age groups and 28-day readmission in those patients less than 85 years of age. Early readmission, under these circumstances, indicates a failure of the inpatient treatment to modify the airways obstruction and lung hyperinflation, and thereby to ameliorate the respiratory muscle load–capacity balance. Future studies should focus on strategies to modify the load–capacity balance and reduce NRD with the aim of promoting safe discharge. The authors acknowledge the limitations of the post-hoc application of an age cut-off of 85 years and wholly appreciate that this is an exploratory analysis and prospective validation will be required to assess 28-day readmission. However, this does not detract from the potential clinical implications of this approach and this analysis ensures that the appropriate target patient group are recruited into any future trials.

Clinical deterioration during admission

We have shown that increases in EMG_{para} predicted worsening of dyspnoea during hospital admission. NRD has the potential to be used to deliver enhanced monitoring for patients who are either unable to communicate their clinical condition effectively or those who fail to recognise the severity of their symptoms, which is a priority in healthcare systems where clinical resources, in terms of nursing and other clinical personnel, are increasingly being rationed. Although Murphy *et al*¹⁵ found that EMG_{para} distinguished between physician-defined improvement and deterioration, this was only in a small number of episodes. We have reproduced these findings in a much larger unselected cohort. Importantly, $\Delta\text{EMG}_{\text{para}\% \text{max}}$ was the only parameter that correlated with physician-defined deterioration, supporting NRD as a physiological biomarker for the early identification of treatment failure.

Physiological validity of NRD in the acute setting

In this cohort of acutely unwell patients with COPD, we observed a correlation between $\Delta\text{EMG}_{\text{para}\% \text{max}}$ and ΔFEV_1 , supporting the hypothesis that EMG_{para} reflects the resistive

load imposed on the respiratory system during an acute exacerbation. Furthermore, there was a direct relationship between $\Delta\text{EMG}_{\text{para}\% \text{max}}$ and ΔIC , indicating that changes in the elastic and threshold loads imposed by hyperinflation can be detected by EMG_{para} . It appears therefore, that EMG_{para} reflects the changes in pulmonary mechanics that accompany an exacerbation of COPD. While the reduction in NRD with decreasing hyperinflation may be due, in part, to the increase in respiratory muscle length, rather than due to a reduction in NRD,²⁹ animal studies of parasternal intercostal muscle activation at high lung volume have shown that parasternal muscle EMG tends to remain stable despite acute lung hyperinflation.

CONCLUSION

During recovery from an acute exacerbation of COPD requiring hospital admission, change in NRD from admission to discharge predicted 14-day readmission in all age groups and 28-day hospital readmission in patients under 85 years old. In addition, change in NRD between successive inpatient measurements was able to detect worsening dyspnoea and physician-defined clinical deterioration. Second intercostal space parasternal EMG is a novel advanced physiological monitoring tool that may be clinically useful in identifying treatment failure during hospital admission and for predicting safe discharge, which is a priority for all acute healthcare organisations.

Contributors Study concept and design: E-SS, PBM, MIP, NSH, GR, JM, NH. Acquisition, analysis or interpretation of data: E-SS, SM, MR, RH, MK, KO, KH, AD and NH. Drafting of the manuscript: E-SS, SM, PBM, NH. Critical revision of the manuscript for important intellectual content: RH, MR, MK, AD, MIP, KO, KH, NSH, GR, JM and NH. Statistical analysis: E-SS, SM, AD. Obtained funding: NH. Administrative, technical or material support: SM, RH, MR, KH, KO, GR. Study supervision: NH, JM.

Funding E-SS and NH acknowledge funding from Guy's and St Thomas' Charity, and from Philips Research, for the conduct of this study. MIP's contribution to the work was supported by the NIHR Respiratory Biomedical Research Unit at the Royal Brompton & Harefield NHS Foundation Trust and Imperial College, who part fund his salary. AD acknowledges financial support from the Department of Health via the National Institute for Health Research (NIHR) Biomedical Research Centre Award to Guy's & St Thomas' NHS Foundation Trust in partnership with King's College London and King's College Hospital NHS Foundation Trust.

Competing interests E-SS was in receipt of an unrestricted educational grant from Philips Research to develop physiological monitoring techniques in patients with COPD. MIP reports personal fees from Philips during the conduct of the study. PBM reports travel fees to conferences, lecture fees and hospitality from Philips Respironics, and hospitality from Resmed. JM has a patent US20130310699 A1 pending to Guy's and St Thomas' NHS Foundation Trust and King's College London. NH reports salary contributions made to Guy's and St Thomas' NHS Foundation Trust from Philips Respironics during the conduct of the study; salary contribution made to Guy's and St Thomas' NHS Foundation Trust, consultancy, lecture fees and unrestricted grants from Philips Respironics outside the submitted work; consultancy, lecture fees and unrestricted grants from Fisher Paykel outside the submitted work; consultancy, lecture fees and unrestricted grants from Resmed outside the submitted work; consultancy, lecture fees and unrestricted grants from B&D Electromedical outside the submitted work; and lecture fees from Linde outside the submitted work; NH has a patent US20130310699 A1 pending to Guy's and St Thomas' NHS Foundation Trust and King's College London.

Ethics approval London-Bentham Research Ethics Committee.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

REFERENCES

- 1 National Institute of Health and Care Excellence. *CG101 Chronic obstructive pulmonary disease (update): full guideline*. London: National Institute of Health and Care Excellence, 2010.

Chronic obstructive pulmonary disease

- 2 Steer J, Gibson J, Bourke SC. The DECAF score: predicting hospital mortality in exacerbations of chronic obstructive pulmonary disease. *Thorax* 2012;67:970–6.
- 3 Roberts CM, Stone RA, Buckingham RJ, *et al.* Acidosis, non-invasive ventilation and mortality in hospitalised COPD exacerbations. *Thorax* 2011;66:43–8.
- 4 Steer J, Norman EM, Afolabi OA, *et al.* Dyspnoea severity and pneumonia as predictors of in-hospital mortality and early readmission in acute exacerbations of COPD. *Thorax* 2012;67:117–21.
- 5 Royal College of Physicians BTS, British Lung Foundation. Report of the national chronic obstructive pulmonary disease audit 2008: clinical audit of COPD exacerbations admitted to acute NHS trusts across the UK. Royal College of Physicians, 2008.
- 6 Reducing COPD readmissions—a personal and political priority. *Lancet Respir Med* 2013;1:347.
- 7 Burke RE, Coleman EA. Interventions to decrease hospital readmissions: keys for cost-effectiveness. *JAMA Intern Med* 2013;173:695–8.
- 8 Garcia-Aymerich J, Farrero E, Felez MA, *et al.* Risk factors of readmission to hospital for a COPD exacerbation: a prospective study. *Thorax* 2003;58:100–5.
- 9 Bahadori K, Fitzgerald JM. Risk factors of hospitalization and readmission of patients with COPD exacerbation—systematic review. *Int J Chron Obstruct Pulmon Dis* 2007;2:241–51.
- 10 Wong AW, Gan WQ, Burns J, *et al.* Acute exacerbation of chronic obstructive pulmonary disease: influence of social factors in determining length of hospital stay and readmission rates. *Can Respir J* 2008;15:361–4.
- 11 Cao Z, Ong KC, Eng P, *et al.* Frequent hospital readmissions for acute exacerbation of COPD and their associated factors. *Respirology* 2006;11:188–95.
- 12 Smith GB, Prytherch DR, Meredith P, *et al.* The ability of the National Early Warning Score (NEWS) to discriminate patients at risk of early cardiac arrest, unanticipated intensive care unit admission, and death. *Resuscitation* 2013;84:465–70.
- 13 Gao H, McDonnell A, Harrison DA, *et al.* Systematic review and evaluation of physiological track and trigger warning systems for identifying at-risk patients on the ward. *Intensive Care Med* 2007;33:667–79.
- 14 Moxham J, Jolley C. Breathlessness, fatigue and the respiratory muscles. *Clin Med* 2009;9:448–52.
- 15 Murphy PB, Kumar A, Reilly C, *et al.* Neural respiratory drive as a physiological biomarker to monitor change during acute exacerbations of COPD. *Thorax* 2011;66:602–8.
- 16 Luo YM, Moxham J. Measurement of neural respiratory drive in patients with COPD. *Respir Physiol Neurobiol* 2005;146:165–74.
- 17 Steier J, Jolley CJ, Polkey MI, *et al.* Nocturnal asthma monitoring by chest wall electromyography. *Thorax* 2011;66:609–14.
- 18 Reilly CC, Ward K, Jolley CJ, *et al.* Neural respiratory drive, pulmonary mechanics and breathlessness in patients with cystic fibrosis. *Thorax* 2011;66:240–6.
- 19 Stevenson NJ, Walker PP, Costello RW, *et al.* Lung mechanics and dyspnea during exacerbations of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2005;172:1510–6.
- 20 Miller MR, Hankinson J, Brusasco V, *et al.* Standardisation of spirometry. *Eur Respir J* 2005;26:319–38.
- 21 Bestall JC, Paul EA, Garrod R, *et al.* Usefulness of the Medical Research Council (MRC) Dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. *Thorax* 1999;54:581–6.
- 22 Borg GA. Psychophysical bases of perceived exertion. *Med Sci Sports Exerc* 1982;14:377–81.
- 23 Mackay AJ, Donaldson GC, Patel AR, *et al.* Usefulness of the chronic obstructive pulmonary disease assessment test to evaluate severity of COPD exacerbations. *Am J Respir Crit Care Med* 2012;185:1218–24.
- 24 Ries AL. Minimally clinically important difference for the UCSD Shortness of Breath Questionnaire, Borg Scale, and Visual Analog Scale. *COPD* 2005;2:105–10.
- 25 McGhan R, Radcliff T, Fish R, *et al.* Predictors of rehospitalization and death after a severe exacerbation of COPD. *Chest* 2007;132:1748–55.
- 26 Gudmundsson G, Gislason T, Janson C, *et al.* Risk factors for rehospitalisation in COPD: role of health status, anxiety and depression. *Eur Respir J* 2005;26:414–19.
- 27 Almagro P, Barreiro B, Ochoa de Echaguen A, *et al.* Risk factors for hospital readmission in patients with chronic obstructive pulmonary disease. *Respiration* 2006;73:311–17.
- 28 Steer J, Gibson GJ, Bourke SC. Predicting outcomes following hospitalization for acute exacerbations of COPD. *QJM* 2010;103:817–29.
- 29 Kim MJ, Druz WS, Sharp JT. Effect of muscle length on electromyogram in a canine diaphragm strip preparation. *J Appl Physiol* 1985;58:1602–7.

THORAX

Neural respiratory drive predicts clinical deterioration and safe discharge in exacerbations of COPD

Eui-Sik Suh, Swapna Mandal, Rachel Harding, Michelle Ramsay, Meera Kamalanathan, Katherine Henderson, Kevin O'Kane, Abdel Douiri, Nicholas S Hopkinson, Michael I Polkey, Gerrard Rafferty, Patrick B Murphy, John Moxham and Nicholas Hart

Thorax 2015 70: 1123-1130 originally published online July 20, 2015
doi: 10.1136/thoraxjnl-2015-207188

Updated information and services can be found at:
<http://thorax.bmj.com/content/70/12/1123>

These include:

Supplementary Material

Supplementary material can be found at:
<http://thorax.bmj.com/content/suppl/2015/07/20/thoraxjnl-2015-207188.DC1.html>

References

This article cites 27 articles, 13 of which you can access for free at:
<http://thorax.bmj.com/content/70/12/1123#BIBL>

Open Access

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections

Articles on similar topics can be found in the following collections

[Open access](#) (168)
[Airway biology](#) (1034)
[Lung function](#) (742)

Notes

To request permissions go to:
<http://group.bmj.com/group/rights-licensing/permissions>

To order reprints go to:
<http://journals.bmj.com/cgi/reprintform>

To subscribe to BMJ go to:
<http://group.bmj.com/subscribe/>